Idorsia's treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product' category

Core Insights - Idorsia Ltd has received the inaugural Prix Galien Bridges Award for its novel treatment for insomnia disorder, recognized as the "Best Biotechnology & Pharmaceutical Product" [1][7] - The award highlights the importance of scientific innovation in advancing patient care and acknowledges Idorsia's commitment to improving healthcare [2][3] Company Overview - Idorsia aims to challenge accepted medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [10][11] - The company is headquartered near Basel, Switzerland, and focuses on small-molecule drugs that can change treatment paradigms for various conditions [11] Product Development - The dual orexin receptor antagonist developed by Idorsia is the first and only drug of its kind approved in Europe for treating insomnia disorder, showcasing a significant breakthrough in life sciences [7][11] - The research team has been studying orexin and its receptors since 1998, leading to the development of a treatment that promotes natural sleep architecture while minimizing morning after-effects [3][8] Insomnia Disorder Insights - Insomnia disorder affects approximately 9.2% of the working-age population in Switzerland, characterized by difficulty in initiating or maintaining sleep, which significantly impacts daytime functioning [6] - The orexin system plays a crucial role in regulating wakefulness, and its overactivity is a key driver of insomnia, making it a target for therapeutic intervention [8]